Assessment of the REPLACE study composite endpoint in the PATENT study and association with long-term outcomes in riociguat-treated patients.

Assessment of the REPLACE study composite endpoint in the PATENT study and association with long-term outcomes in riociguat-treated patients.

Contenido principal del artículo

Gérald Simonneau
Marius M. Hoeper
Hossein Ardeschir Ghofrani
Paul A. Corris
Stephan Rosenkranz
Ekkehard Grüning
Jim White
Vallerie V. Mclaughlin
David Langleben
Christian Meier
Dennis Busse
Frank Kleinjung
Raymond L. Benza

Resumen

Assessment of the REPLACE study composite endpoint in the PATENT

Detalles del artículo

Referencias (VER)

Hoeper MH, et al. Eur Respir J 2017;50:PA2417.

Ghofrani HA, et al. N Engl J Med 2013;25:369:330–40.

Ghofrani HA, et al. Lancet Respir Med 2016;4:361–71.

Li F, et al. J Am Stat Assoc 2018;113:390–400.